June 1 (Reuters) – Coherus BioSciences Inc (CHRS.O) said on Thursday it plans to launch a biosimilar of AbbVie Inc’s (ABBV.N) Humira in July at a list price of $995 per carton, representing a discount of about 85% from the blockbuster arthritis drug. The annual cost of the biosimilar, branded as Yusimry, will be around $13,000, compared with $90,000 for Humira, Coherus said. Coherus has also partnered with Billionaire entrepreneur Mark Cuban’s pharmaceuticals startup to sell the biosimilar at $569.27 plus dispensing and shipping fees. The Mark Cuban Cost Plus Drug Company provides generic drugs through direct contracts with manufacturers and charges a standard…
Author: Rutali Thakur
Abstract Background and aims The cause of Crohn’s Disease (CD) is unknown, but the current hypothesis is that microbial or environmental factors induce gut inflammation in genetically susceptible individuals, leading to chronic intestinal inflammation. Case-control studies of CD patients have catalogued alterations in the gut microbiome composition; however, these studies fail to distinguish if the altered gut microbiome composition is associated with initiation of CD or is the result of inflammation or drug treatment.
UnitedHealth is backing off a controversial plan to require prior authorizations for colonoscopies and other endoscopic procedures. But the debate over insurer sign-offs that it stoked will likely linger. Why it matters: While prior authorizations are supposed to ensure that health services are medically necessary, critics say they can create barriers to care and drown the health system in red tape. Driving the news: UnitedHealth, the biggest commercial health insurer in the U.S., planned today to start requiring prior authorizations for most endoscopic procedures, including some to treat cancer and gastrointestinal diseases.
Gastroenterologists’ average annual income rose from $453,000 in 2021 to $501,000 in 2022 — an increase of 11%, second only to oncologists’ 13% bump, according to the 2023 Medscape Gastroenterologist Compensation Report. In terms of 2022 income, gastroenterologists finished fifth among the 29 specialties in the Medscape survey of more than 10,000 physicians. The top earners were plastic surgeons ($619,000), orthopedists ($573,000), cardiologists ($507,000), and urologists ($506,000). For employed physicians, compensation figures include salary, bonus, and profit-sharing contributions. For self-employed physicians, they include earnings after taxes and deductible business expenses before income tax. Only full-time salaries were included in the results.
Newswise — New guidelines for the pharmacological treatment of chronic idiopathic constipation (CIC) in adults are the first to recommend magnesium oxide and senna as evidence-based treatments. The first joint clinical practice guideline developed by the American College of Gastroenterology (ACG) and the American Gastroenterological Association (AGA) published today in both societies’ scientific journals, ACG’s The American Journal of Gastroenterology and AGA’s Gastroenterology. An accompanying Clinical Support Decision Tool is available in Gastroenterology. Under the leadership of Lin Chang, MD, AGAF, FACG, and William D. Chey, MD, AGAF, FACG, a multidisciplinary guideline panel conducted systematic reviews of various over-the-counter and prescription pharmacological agents available for the treatment of…
Design innovations for duodenoscopes to reduce or eliminate infections have accelerated in the past few years. What are the current innovations and what is on the horizon? Will these designs improve patient safety? What are the financial implications for GI practices? AGA’s Innovation in Duodenoscope Design program aims to address these questions and more. The program includes webinars, editorials and podcasts that will examine the current landscape of duodenoscope designs and how it will impact clinical practice.
TAMPA, Fla., May 22, 2023 (GLOBE NEWSWIRE) — Florida Medical Clinic announced today that it plans to add a Gastroenterology practice to its new Epperson/Watergrass Campus in July. The 32,000-square-foot campus opened in late September 2022. It sits in the heart of the Epperson and Watergrass neighborhoods in Wesley Chapel. The campus is designed to serve residents of these two new growing communities as well as surrounding areas, including Wesley Chapel and Dade City.
In recent years, we have seen a growing trend of large corporations acquiring primary care clinics. Earlier this month, the New York Times published an article entitled “Corporate Giants Buy Up Primary Care Practices at Rapid Pace.” While the title may accurately capture the pattern at the surface level, the article does not provide the full context and nuance needed to deeply understand this trend and its implications. Health plans, private equity firms, and retailers are absolutely racing to buy up physician practices. But the rise in ownership isn’t a guaranteed success — nor is it a guaranteed failure for the industry.
G&H What has recent research revealed about the rise in esophageal adenocarcinoma despite screening and surveillance for Barrett esophagus? AC Esophageal adenocarcinoma (EAC) has been increasing for several decades, and no one understands exactly what changed in our environment to cause the rise. There are etiologies one can speculate on. Obesity has increased and along with it, gastroesophageal reflux disease (GERD) has increased, although neither risk factor can entirely explain the rise in incidence. Obesity and GERD are known independent risk factors for EAC, but the odds ratios would only explain a fraction of the increasing incidence. We do not know what…
Though much of Freenome’s focus has been on its blood test for the early detection of colorectal cancer, the company is also in the process of building out its multiomics platform to be able to test for other types of cancer, too. A new acquisition aims to accelerate the latter goal. Freenome put down 13 million British pounds—or about $16.1 million—to absorb Oncimmune Limited and Oncimmune Europe GmbH, two subsidiaries of U.K.-based Oncimmune, another maker of early cancer diagnostics.